(Q31159257)

English

Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pertussis vaccine

1 reference

based on heuristic

inferred from title

author name string

F Bailleux

1

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

L Coudeville

2

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

A Kolenc-Saban

3

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

J Bevilacqua

4

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

L Barreto

5

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

P André

6

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

language of work or name

0 references

publication date

2 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

3903-3908

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Epidemiology of pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Infant pertussis: who was the source?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Pertussis sources of infection and routes of transmission in the vaccination era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Immunity to pertussis 5 years after booster immunization during adolescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Immune responses to Bordetella pertussis infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Serologic response and antibody-titer decay in adults with pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Adult immunization with acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Duration of humoral immunity to common viral and vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Repeated-measures models to evaluate a hepatitis B vaccination programme.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.089

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.04.089

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31159257&oldid=1607964956"